Drug intelligence / Profile preview

escitalopram + eszopiclone

Development stage
Unknown
Lead developer
Allergan
Modality
Small Molecules
Administration
Oral
01

Overview

This is a **combination of escitalopram**, a selective serotonin reuptake inhibitor (SSRI), and **eszopiclone**, a non-benzodiazepine hypnotic agent. Escitalopram increases serotonin levels in the brain by inhibiting its reuptake, primarily used for major depressive disorder and generalized anxiety disorder. Eszopiclone is a GABA-A receptor positive allosteric modulator, used to treat insomnia by enhancing central nervous system inhibition to promote sleep. This combination is explored for patients with comorbid generalized anxiety disorder and insomnia, with studies showing that coadministration improves sleep, daytime functioning, anxiety, and mood compared to escitalopram monotherapy. The combination is generally well tolerated, though increased CNS depression (such as somnolence, dizziness, and confusion) may occur[1][3][5][6].

Brand names
LunestaLexapro
Other names
escitalopram and eszopicloneescitalopram plus eszopiclone
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)SERT allosteric site (Serotonin transporter allosteric site)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on escitalopram + eszopiclone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on escitalopram + eszopiclone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call